Clinical trials in Potsdam – page 89

1 819 clinical trials in Potsdam, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Potsdam at a glance

1 819

clinical trials

Research sites1

Quick filters

1 819 trials in Potsdam

Open in trial search

Coronary artery disease

Not recruiting

A Study of XC001 Gene Therapy with Bypass Surgery for Patients with Coronary Artery Disease and Weakened Heart Function at Risk for Incomplete Treatment

Registered drug

A Study of XC001 Gene Therapy with Bypass Surgery for Patients with Coronary Artery Disease and Weakened Heart Function at Risk for Incomplete Treatment

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Adenosine
Sponsor:Xylocor Therapeutics Inc.

Contact Research Centre

Small cell lung cancer extensive stage+2

Not recruiting

Testing Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition

InvestigationalNo placebo

Testing Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:AIO-Studien gGmbH

Contact Research Centre

Rheumatoid arthritis

Not recruiting

A study testing tulisokibart for people with rheumatoid arthritis who have not responded well enough to previous treatments

Investigational

A study testing tulisokibart for people with rheumatoid arthritis who have not responded well enough to previous treatments

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Tulisokibart
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Malignant melanoma

Not recruiting

Study of Acasunlimab Alone and Combined With Pembrolizumab in Patients With Advanced Skin Melanoma That Returned or Did Not Respond to Prior Treatment

Registered drugNo placebo

Study of Acasunlimab Alone and Combined With Pembrolizumab in Patients With Advanced Skin Melanoma That Returned or Did Not Respond to Prior Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Acasunlimab
Sponsor:Genmab A/S

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

Study comparing semaglutide and dapagliflozin taken separately or combined in one tablet for type 2 diabetes patients

Registered drugNo placebo

Study comparing semaglutide and dapagliflozin taken separately or combined in one tablet for type 2 diabetes patients

Registered drugNo placebo

Germany

Participants:18–64 years · Healthy volunteers
Substances:Dapagliflozin
Sponsor:Novo Nordisk A/S

Contact Research Centre

Amyotrophic lateral sclerosis

Not recruiting

Study of Cromolyn Inhalation Treatment for Patients with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)

Investigational

Study of Cromolyn Inhalation Treatment for Patients with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Sodium Cromoglicate
Sponsor:Phenonet Inc.

Contact Research Centre

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Major depression

Not recruiting

Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo

Investigational

Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Lavender Oil
Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease+2

Not recruiting

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Registered drug

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Phosphatidyl choline
Sponsor:Opella Healthcare Group S.A.S.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Potsdam

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative, HER2-positive, and hormone receptor-positive variants. Research encompasses new combination therapies and targeted treatments.

Early-stage breast cancer interventions
HPV-positive oropharyngeal cancer treatments
Advanced treatment strategies

Multiple studies are evaluating novel drug combinations and personalized therapeutic approaches.

02 Dermatological Studies

Clinical research targeting various skin conditions, including atopic dermatitis and chronic skin disorders. Studies focus on both topical and systemic treatments.

Actinic keratosis treatments
Hidradenitis suppurativa therapy
Plaque psoriasis management

Investigations include both traditional and innovative therapeutic approaches for skin conditions.

03 Neurological Research

Studies focusing on multiple sclerosis treatment options, evaluating new medications and comparing their effectiveness to existing therapies.

Relapsing-remitting MS treatments
Novel therapeutic approaches
Disease modification strategies

Research aims to improve treatment outcomes and quality of life for patients with neurological conditions.

04 Cardiovascular Studies

Research focusing on cardiovascular disease management and innovative treatments for related conditions, including studies on lipid management.

Lipoprotein management
Cholesterol reduction therapies
Cardiovascular risk prevention

Trials aim to reduce major cardiovascular events and improve patient outcomes.

Back to Germany All countries